Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Noticed Labeling Problems With Roxane Drugs Six Months Before Morphine Alert

This article was originally published in The Pink Sheet Daily

Executive Summary

Roxane's high-potency morphine packaging is being redesigned with bold colors to distinguish it from other products after overdoses including deaths.

You may also be interested in...



Roxane's Redesigned Morphine Carton Reflects Orderly Rollout After Safety Concern

FDA allows existing stock to be used up over the course of a year after the new color-coded container for the high-potency product was approved.

Roxane's Redesigned Morphine Carton Reflects Orderly Rollout After Safety Concern

FDA allows existing stock to be used up over the course of a year after the new color-coded container for the high-potency product was approved.

Dangerous Clutter: FDA Takes On Errors Caused By Drug Labels, Packaging

Reducing the amount of unnecessary information on drug labels is one of several key ways to stop dangerous medication errors, a panel that is helping FDA develop guidance on the subject agreed

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel